Connect with us

ANTHEM

Anthem Biosciences Limited (NSE: Anthem) Q4 FY26: Revenue Up 26%, PAT Surges 130%

Anthem Biosciences Limited (NSE: ANTHEM) announced its Q4 FY26 results with a 26% YoY revenue growth and a 129.8% surge in PAT.

abhinav tiwari

Published

on

Anthem Biosciences Limited Q4 FY26 Results

Anthem Biosciences Limited (NSE: ANTHEM) announced its audited consolidated financial results for the quarter and year ended March 31, 2026, showcasing robust growth. For the quarter, consolidated revenue from operations stood at ₹6,109 Mn, marking a 26.4% year-on-year increase. The company’s EBITDA for the quarter was ₹3,184 Mn, with margins at 48.1%, reflecting strong operational efficiency. Notably, the Profit After Tax (PAT) for Q4 FY26 was ₹1,898 Mn, a significant 129.8% rise compared to the same period last year.

Full Year Financial Highlights

For FY26, Anthem Biosciences Limited reported consolidated revenue from operations of ₹21,243 Mn, a 15.2% increase from the previous year. The company’s EBITDA for the full year was ₹9,896 Mn, with margins at 43.4%. The PAT for FY26 was ₹5,918 Mn, showing a 31.1% growth year-on-year. The company’s commitment to prudent cost management and focus on long-term value creation has enabled it to expand profitability margins while delivering this revenue growth.

Looking Ahead

Commenting on the results, Ajay Bhardwaj, Chairman, MD, and CEO of Anthem Biosciences Limited, said, “We ended the financial year 2025–26 on a strong note, with our highest revenue quarter ever in Q4FY26. Anthem’s commitment to prudent cost management and focus on long-term value creation has enabled us to expand profitability margins while delivering this revenue growth. The Company continues to maintain a healthy financial position and remains committed to delivering sustainable growth across all business segments. As we step into financial year 2026–27, our priorities remain clear: to build one of the most agile, science-led, and future-ready CRDMO platforms in the world.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ANTHEM
Healthcare › Biotechnology
APPROACHING RESISTANCE
76
Fundamental
84
Technical
80
Overall

1W -2.79%
1M +13.29%
3M +3.72%
P/E: 86.1 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Anthem rises 14.7% over three months, with buying pressure holding steady. The PEG stands at 25.44 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 24.2% are impressive but need to be sustained — any compression would be a red flag. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 19 of recent sessions versus 11 for sellers — a healthy accumulation pattern. The stock rises 14.7% in three months on 14.4% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Anthem Biosciences Limited.

ANTHEM

Anthem Biosciences Limited (NSE: Anthem) Q2 & H1 FY27 Results: Robust Performance and Margin Expansion

Anthem Biosciences Limited (NSE: ANTHEM) reports strong Q2 & H1 FY27 results with consolidated revenue up 7.2% and EBITDA margins at 50.6%.

jyoti sharma

Published

on

Anthem Biosciences Limited NSE Anthem Q2 FY27 Results

Anthem Biosciences Limited (NSE: ANTHEM) has announced robust financial results for the second quarter and half year of FY27, showcasing significant growth and margin expansion. Consolidated revenue from operations for the quarter stood at ₹5,940 Mn, up 7.9% YoY, while EBITDA was ₹3,304 Mn, marking a 24.1% increase. The company’s profit after tax (PAT) for Q2FY27 was ₹2,115 Mn, reflecting a 21.9% rise compared to the same period last year.

Half-Year Financial Highlights

For the first half of FY27, Anthem Biosciences Limited reported consolidated revenue from operations of ₹10,123 Mn, a decrease of 7.2% YoY. However, the company’s EBITDA for H1 FY27 was ₹5,059 Mn, with margins at 46.2%. The PAT for H1 FY27 was ₹3,314 Mn, showing a 7.2% increase compared to H1 FY26.

Margin and Cost Efficiency

Anthem Biosciences Limited has demonstrated strong performance in maintaining and expanding its EBITDA and PAT margins. The company’s ability to sustain growth is attributed to strict discipline around cost efficiencies, yield optimization, and workforce productivity. This has further solidified its industry-leading margins, positioning the company well to sustain this performance throughout the year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ANTHEM
Healthcare › Biotechnology
APPROACHING RESISTANCE
76
Fundamental
84
Technical
80
Overall

1W -2.79%
1M +13.29%
3M +3.72%
P/E: 86.1 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Anthem posts a 5.8% three-month gain, but softens in the last few weeks. The PEG stands at 5.22 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 28.7% reflect exceptional pricing power and operational efficiency. The stock gives back 9.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 5.22 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.

Continue Reading

ANTHEM

Anthem Biosciences Limited (NSE: ANTHEM) breaks out, gains 5% intraday

Anthem Biosciences Limited (NSE: ANTHEM) stock cleared its 6M resistance trendline and is up 5% intraday at ₹896.8.

Blogger Kapil Rohilla TradeAlone

Published

on

Anthem Biosciences Limited NSE: ANTHEM breaks out

Anthem Biosciences Limited (ANTHEM) breaks out with a +5% gain today, clearing its 6-month resistance trendline. This move is driven by strong technical momentum, with the stock now trading 12.0% above the resistance level of ₹789. Anthem Biosciences, a key player in the biotechnology sector, is showing robust performance despite the extended nature of this move, which is 10% above the 50-DMA.

Technical setup — trendlines & DMA

The current trendline structure for Anthem Biosciences shows a 6-month support floor at ₹765.7, which is 14.62% below today’s price. The resistance trendline, previously at ₹789.08, has been decisively broken, indicating a strong upward momentum. The 50-DMA at ₹776.6 is above the 200-DMA at ₹705.7, signaling a bullish trend. The stock is currently trading in the upper third of its 52-week range, suggesting that much of the recent move is already priced in, though it remains near yearly highs.

6M Trendline — Intraday Snapshot
BREAKOUT₹750₹800₹85020 May17 Jun15 Jul11 Aug

Snapshot: ₹896.80 on 2026-08-11 (chart frozen at publication)

Fundamentals & business context

With a PE of 84.5, Anthem Biosciences’ valuation appears stretched, especially when considering its 28.7% profit margin and a revenue CAGR of 26.2%. This suggests that the market may be pricing in future growth expectations, though the current valuation seems high relative to the company’s current earnings. Institutional ownership stands at 12.5%, indicating a cautious yet interested stance from smart money. There is no NSE catalyst today, making this move primarily technical in nature.

ANTHEM
Holdings Analysis
Key strengths & risk signals
80
Overall
76
Fundamental
84
Technical
Risks (1)
OVERVALUED! PEG of 5.59 means expensive relative to growth rate.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (881.8) is above 200-day average (790.7) - positive signal.
GOOD YEAR! Stock gained 40.8% in the last year.
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 1,208,426 vs down days: 438,053. Ratio: 2.76x

Algorithmic scorecard

The overall scorecard reflects a technically strong but fundamentally mixed picture. The strongest signals come from the company’s excellent revenue growth and very low debt levels, indicating solid financial health and consistent business performance. However, the weakest signals are the overvalued PEG ratio and negligible dividend yield, which pose risks of overpricing and lack of income generation for investors. These factors need careful consideration despite the strong technical performance.

Fundamental & Technical AnalysisNSE: ANTHEM
80Overall
76Fundamental
84Technical
Growth Quality28 / 30
Revenue CAGR: 26.2% (EXCELLENT, 15/15). Profit CAGR: 15.4% (VERY GOOD, 13/15).
Profit Margin9 / 10
EXCELLENT EFFICIENCY! 29.9% profit margin - company keeps strong profits.
PEG Valuation0 / 10
OVERVALUED! PEG of 5.59 means expensive relative to growth rate.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.21% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.04 - excellent financial health.
Public Holding16 / 20
LESS PUBLIC HOLDING! 16.42% public ownership - good institutional/promoter control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (881.8) is above 200-day average (790.7) - positive signal.
Price Position8 / 10
STRONG POSITION! Current price (931.5) is above both moving averages.
Trend Pattern10 / 20
AT RESISTANCE! Stock is at key resistance level.
52W Performance10 / 10
GOOD YEAR! Stock gained 40.8% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 1,208,426 vs down days: 438,053. Ratio: 2.76x
RSI3 / 5
NEUTRAL! RSI at 57.8 - balanced momentum.
52W Range5 / 5
STRONG! Trading at 86.0% of 52W range - near yearly highs.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - -2.8% (1 week), 13.3% (1 month), 3.7% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

Management provided forward-looking guidance indicating that Q1 FY27 will be the softest quarter, with growth expected from Q2 onwards. They anticipate a normalization of the tax rate to about 25% and expect to maintain margins due to order book visibility and cost efficiencies. Additionally, ESOP costs are expected to decline from FY28. On the investment front, Unit 4 is planned for completion by the end of FY28, adding significant capacity. The targeted capex for FY27 is set at approximately Rs. 700 crores, reflecting continued investment in growth and capacity expansion.

Get all details on ANTHEM — P&L, peers, shareholding and more on TradeAlone.

Continue Reading

ANTHEM

Anthem Biosciences Limited (NSE: ANTHEM) breaks below support, falls 5%

Anthem Biosciences Limited (NSE: ANTHEM) stock price falls 5% intraday to ₹746.1, breaking below support in a sectoral breakdown..

abhinav tiwari

Published

on

Anthem Biosciences Limited NSE: ANTHEM breaks below support

Anthem Biosciences Limited (ANTHEM) breaks below support, falling -5% to ₹746.1 on the NSE on 22 Jul 2026, backed by the recent investor presentation announcement on July 21, 2026. The stock’s decline today appears to be a reaction to the presentation, where the company discussed its strategic direction and financial performance amidst market uncertainties. This move is somewhat isolated to Anthem, as the broader biotech sector remains stable.

Technical setup — trendlines & DMA

From a technical perspective, Anthem Biosciences is currently in a breakdown phase, having fallen below its 6-month support trendline of ₹757.3. The stock is now trading 1.50% below this support level, indicating a potential shift in short-term momentum. Resistance remains at ₹810.61, which is 8.65% above the current price. The 50-day moving average (DMA) at ₹770.8 is above the 200-DMA at ₹701.3, suggesting a bullish underlying trend, though the stock is currently trading below both moving averages. In terms of its 52-week range, the stock is positioned in the middle third, 57% above the 52-week low and 14.6% below the 52-week high, indicating that a significant portion of its potential upside may already be priced in.

6M Trendline — Intraday Snapshot
BREAKDOWN₹760₹78020 May10 Jun2 Jul22 Jul

Snapshot: ₹746.10 on 2026-07-22 (chart frozen at publication)

Fundamentals & business context

On the fundamental front, Anthem Biosciences presents a mixed picture. With a PE ratio of 74.6 and profit margins of 27.8%, the stock appears richly valued relative to its earnings. However, its revenue CAGR of 26.2% over the past five years suggests strong growth potential. The company’s institutional holding of 12.3% indicates a level of confidence from sophisticated investors, though it is not overwhelmingly high. There was no specific NSE catalyst today beyond the investor presentation, which may have contributed to the stock’s decline as investors digested the information provided.

ANTHEM
Holdings Analysis
Key strengths & risk signals
80
Overall
76
Fundamental
84
Technical
Risks (1)
OVERVALUED! PEG of 5.59 means expensive relative to growth rate.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (881.8) is above 200-day average (790.7) - positive signal.
GOOD YEAR! Stock gained 40.8% in the last year.
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 1,208,426 vs down days: 438,053. Ratio: 2.76x

Algorithmic scorecard

The overall algorithmic scorecard for Anthem Biosciences reflects a technically strong but fundamentally weaker profile. Two of the strongest signals are the company’s excellent revenue CAGR of 26.2%, indicating robust growth, and its very low debt levels with a D/E ratio of 0.00, showcasing strong financial health. On the flip side, the stock’s overvaluation with a PEG ratio of 4.84 and negligible dividend yield of 0.26% are significant weaknesses. The overvaluation suggests that the stock may be pricing in future growth that has not yet materialized, while the low dividend yield offers little income to investors, making the stock less attractive from an income perspective.

Fundamental & Technical AnalysisNSE: ANTHEM
80Overall
76Fundamental
84Technical
Growth Quality28 / 30
Revenue CAGR: 26.2% (EXCELLENT, 15/15). Profit CAGR: 15.4% (VERY GOOD, 13/15).
Profit Margin9 / 10
EXCELLENT EFFICIENCY! 29.9% profit margin - company keeps strong profits.
PEG Valuation0 / 10
OVERVALUED! PEG of 5.59 means expensive relative to growth rate.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.21% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.04 - excellent financial health.
Public Holding16 / 20
LESS PUBLIC HOLDING! 16.42% public ownership - good institutional/promoter control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (881.8) is above 200-day average (790.7) - positive signal.
Price Position8 / 10
STRONG POSITION! Current price (931.5) is above both moving averages.
Trend Pattern10 / 20
AT RESISTANCE! Stock is at key resistance level.
52W Performance10 / 10
GOOD YEAR! Stock gained 40.8% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 1,208,426 vs down days: 438,053. Ratio: 2.76x
RSI3 / 5
NEUTRAL! RSI at 57.8 - balanced momentum.
52W Range5 / 5
STRONG! Trading at 86.0% of 52W range - near yearly highs.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - -2.8% (1 week), 13.3% (1 month), 3.7% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

Management’s forward guidance for Anthem Biosciences is optimistic, with aspirations to maintain a historical growth rate of upwards of 20%. They anticipate growth in the GLP-1 market as an alternative to Chinese imports and aim for a 20% growth in the specialty ingredients business. The ramp-up of newly launched commercial molecules is expected over the next two to three years. Additionally, the company is open to acquisitions in India and abroad if they align with their strategic goals. This outlook suggests a focus on both organic growth and strategic acquisitions to drive future performance.

Get all details on ANTHEM — P&L, peers, shareholding and more on TradeAlone.

Continue Reading

Trending